Clinical Trials
95 trialsNCT05564390 2026-05-26
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07605416 2026-05-26
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT06954987 2026-05-13
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT03477539 2026-05-05
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT07365306 2026-04-24
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT03164057 2026-04-23
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT07349771 2026-04-16
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
Mayo Clinic
Phase 2 Not yet recruiting
NCT02250937 2026-04-15
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00792948 2026-04-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03786783 2026-04-13
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04214249 2026-04-13
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06859424 2026-03-17
ACCELERATE
Center for International Blood and Marrow Transplant Research
Phase 2 Recruiting
NCT06059391 2026-03-10
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 2 Recruiting
NCT04195633 2026-02-27
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06207799 2026-02-19
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07228624 2026-02-19
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT05656248 2026-02-04
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01511562 2026-01-30
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT07046078 2026-01-30
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04262843 2026-01-28
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04994808 2026-01-26
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT03317899 2025-12-17
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Thomas Jefferson University
Phase 2 Completed
NCT03346135 2025-12-05
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06128070 2025-10-31
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 2 Recruiting
NCT01760655 2025-10-30
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT05031897 2025-10-30
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Phase 2 Recruiting
NCT06905509 2025-09-29
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
University of California, Davis
Phase 2 Recruiting
NCT03712878 2025-08-22
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT04530487 2025-06-29
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06815003 2025-06-27
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
Phase 2 Recruiting
NCT05827549 2025-06-06
ReCALL
Asan Medical Center
Phase 2 Recruiting
NCT01532635 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Phase 2 Terminated
NCT00936936 2024-08-26
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04526288 2024-05-23
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03128359 2024-01-09
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Phase 2 Completed
NCT04205240 2023-09-28
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT01374841 2023-06-28
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
European Institute of Oncology
Phase 2 Unknown
NCT01256398 2023-04-04
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02807883 2023-01-20
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00912223 2022-12-09
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Medical College of Wisconsin
Phase 2 Completed
NCT01168219 2022-08-04
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT03303950 2022-05-05
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
University of Utah
Phase 2 Terminated
NCT00629798 2021-09-24
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03881735 2021-03-10
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT00813124 2021-02-11
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00591630 2021-02-02
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Completed